comparemela.com
Home
Live Updates
Atara Biotherapeutics, Inc.: CHMP Recommends Approval of Atara Biotherapeutics Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease : comparemela.com
Atara Biotherapeutics, Inc.: CHMP Recommends Approval of Atara Biotherapeutics' Ebvallo (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease
EbvalloTM on Track to be the First Ever Allogeneic T-Cell Therapy Approved Positive Opinion Based on Pivotal Phase 3 ALLELE Study Demonstrating a Favorable Risk-Benefit Profile European Commission
Related Keywords
France
,
Norway
,
California
,
United States
,
Iceland
,
Liechtenstein
,
South San Francisco
,
United Kingdom
,
French
,
Pierre Fabre
,
Eric Hyllengren
,
Alex Chapman
,
Eric Ducournau
,
Sylvain Choquet
,
Laure Sgandurra
,
Pascal Touchon
,
Atara Biotherapeutics Inc
,
Linkedin
,
Twitter
,
European Commission
,
Drug Administration
,
European Commission Approval
,
Nasdaq
,
Exchange Commission
,
European Union
,
European Medicines Agency
,
Securities Exchange
,
Health Care
,
Healthcare Products Regulatory Agency
,
Committee For Medicinal Products Human Use
,
Pierre Fabre Foundation
,
First Ever Allogeneict Cell Therapy
,
Opinion Based
,
Pivotal Phase
,
Favorable Risk Benefit
,
Commission Approval Expected
,
Medicinal Products
,
Human Use
,
Clinical Hematology Department
,
Authorization Application
,
Reliance Procedure
,
Breakthrough Therapy Designation
,
Pierre Fabre Oncology
,
Pierre Fabre Dermatology
,
Pierre Fabre Oral
,
South San
,
Securities Act
,
Securities Exchange Act
,
Southern California
,
Financial Condition
,
Katara
,
Iotherapeutics
,
Thmp
,
Ecommends
,
Approval
,
Ebvallo
,
Tabelecleucel
,
Treatment
,
Epstein
,
Arr
,
Virus
,
Positive
,
Most
,
Transplant
,
Ymphoproliferative
,
Disease
,
comparemela.com © 2020. All Rights Reserved.